Thousands of donated kidneys go to waste every year due to the lack of a reliable, real-time method to assess organ viability. Surgeons are left making difficult decisions about whether to proceed with a transplant, often without objective data on the organ’s condition. This contributes to higher failure rates, increased strain on healthcare systems, and leaves many patients reliant on dialysis or facing life-threatening complications due to limited organ availability.
To tackle this pressing problem, MedTech startup Accunea has developed RenoSure, a device designed to help kidney transplant assessments. RenoSure uses advanced sensor technology to monitor multiple biomarkers related to kidney function and metabolism, providing surgeons with real-time data on a kidney’s health status. By offering an objective assessment right in the operating room, RenoSure enables clinicians to make better-informed decisions, reducing the likelihood of organ rejection and enhancing transplant success rates.
The device, compact and blood-free, integrates smoothly into current medical workflows without needing additional medications, making it an accessible tool in high-stress transplant settings. As CEO Rob Learney highlights, RenoSure could prevent many viable organs from being discarded, addressing a gap that currently results in high levels of kidney wastage. With a recent €200,000 investment from the Microfluidics Innovation Hub, Accunea is poised to bring this transformative technology to market, aiming to improve outcomes for patients in need of transplants and alleviate pressure on healthcare systems.
Article written by Oliver Johnson
12/11/2024
Source:
MedTech News